On Monday, March 30th, Phase 1 data was released regarding TNX-4800. This is a long-acting human monoclonal antibody designed to combat Borrelia OspA, with the aim of preventing Lyme disease on a seasonal basis. The study provided crucial insights into the potential effectiveness of TNX-4800 in this capacity. This data marks a significant step forward in the ongoing efforts to develop innovative solutions to address the prevalence of Lyme disease.